New RYBREVANT®▼ (amivantamab) Data Showed Long-Term Clinical Response and Safety Profile in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy
- EMEA Innovative Medicine
- New RYBREVANT®▼ (amivantamab) Data Showed Long-Term Clinical Response and Safety Profile in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy
New RYBREVANT®▼ (amivantamab) Data Showed Long-Term Clinical Response and Safety Profile in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy
- X (Twitter)
Copy link